Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3

Status: No longer recruiting

Protocol number: ML17087

Sponsor: Roche Austria GmbH

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of PEGASYS plus 2 different doses of ribavirin on sustained virological response in patients with chronic hepatitis C viral infection, genotype 2 or 3

Brief summary: This study will evaluate the efficacy and safety of PEGASYS plus different doses of ribavirin in patients with CHC, genotype 2 or 3. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals. Target sample size is 648.

Study phase: IV

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Hepatitis C, Chronic

Intervention type: Drug

Intervention name: peginterferon alfa-2a[PEGASYS]

Primary outcome: 1. Efficacy: Sustained virologic response rate at Week 48

Key secondary outcomes: 1. Efficacy: Virologic response rates at Week 24, safety and tolerability, quality of life, comparison of hemoglobin value at Week 24, Safety: Adverse events, laboratory values

Inclusion criteria:

  • adult patients 18-65 years of age;
  • CHC, genotype 2 or 3;
  • abdominal ultrasonography within 3 months before study.

Exclusion criteria:

  • previous interferon or PEGASYS plus ribavirin therapy;
  • anti-neoplastic or immunomodulatory treatment <=6 months before study drug;
  • medical condition associated with chronic liver disease other than CHC;
  • liver cirrhosis, class B or C.

Gender: Males or Females

Age limits: Min: 18 Years Max: 65 Years

Accepts healthy volunteers: No

Anticipated start date: May, 2003

Trial registration date: 08/26/2005

Date last updated: 11/21/2008


Link to trial result

This trial was conducted at the following locations:

Austria

  • Gratwein
  • Graz
  • Innsbruck
  • Krems
  • Linz
  • Oberndorf
  • Oberpullendorf
  • Ried-Innkreis
  • Salzburg
  • Villach
  • Vöcklabruck
  • Wels
  • Wien
  • Wiener Neustadt

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply